# Natera (Signatera)
> Natera is a global leader in cell-free DNA (cfDNA) testing, specializing in oncology, women's health, and organ health. Its flagship oncology product, Signatera, is a personalized, tumor-informed molecular residual disease (MRD) test designed to detect cancer recurrence earlier than standard imaging.
- URL: https://optimly.ai/brand/natera-signatera
- Slug: natera-signatera
- BAI Score: 88/100
- Archetype: Challenger
- Category: Biotechnology
- Last Analyzed: April 10, 2026
## Also Referenced By
- Personalis (NeXT Personal) (https://optimly.ai/brand/personalis-next-personal)
## Buyer Intent Signals
Problems: Standard Radiographic Imaging: Surgical oncologists and radiologists monitoring for recurrence using standard medical imaging (CT, MRI) without molecular enhancement. | Traditional Protein Biomarkers: Monitoring patients through serial measurements of traditional protein-based tumor markers like CEA or CA-125.
Solutions: Best MRD test for colorectal cancer recurrence | personalized liquid biopsy for cancer monitoring | cfDNA testing for oncology | Signatera Medicare coverage indications | how to get a blood test for cancer at home | Tissue-only Pathology: Using standard tissue biopsies at the time of suspected recurrence rather than proactive blood-based monitoring.